Transplant News and Research

RSS

Genzyme announces 2-year data from eliglustat tartrate Phase 2 trial for Gaucher disease

Genzyme Corporation announced today two-year follow-up data from patients enrolled in the phase 2 clinical trial for its investigational oral therapy for Gaucher disease type 1 known as eliglustat tartrate (formerly Genz-112638). Continued improvements were observed across all endpoints, including bone disease, at the two-year timepoint, compared with baseline. The two-year results were presented for the first time today at the Lysosomal Disease Network WORLD Symposium in Miami, Fla.

12 Feb 2010

NMDP Phase III filgrastim trial: Biologics to provide pharmacy management services

Biologics, Inc., the leading cancer management company in the United States, announces that its Oncology Clinical Trial Services division has been selected by the National Marrow Donor Program® (NMDP), a nonprofit organization that facilitates unrelated hematopoietic cell transplants.

12 Feb 2010

First FDA-approved umbilical cord blood stem cells infusion trial in children with cerebral palsy

Medical College of Georgia researchers are conducting the first FDA-approved clinical trial to determine whether an infusion of stem cells from umbilical cord blood can improve the quality of life for children with cerebral palsy.

12 Feb 2010

PARI Pharma commences enrollment in L-CsA Phase 2b efficacy study

PARI Pharma has enrolled the first patient in its Phase 2b clinical trial studying inhaled liposomal cyclosporine A (L-CsA) delivered via a customized Investigational eFlow Nebulizer System. The multinational study is investigating the safety and efficacy of PARI's L-CsA formulation. In previous clinical trials, reactions from physicians and lung transplant recipients to PARI's drug-device combination were encouraging.

11 Feb 2010

Alexion Pharmaceuticals announces financial results for quarter and year ended December 31, 2009

Alexion Pharmaceuticals, Inc. today announced financial results for the quarter and year ended December 31, 2009. For the three months ended December 31, 2009, Alexion Pharmaceuticals, Inc. ("Alexion" or, the "Company") reported net product sales of Soliris® (eculizumab) of $110.6 million, reflecting strong additions of new patients, compared to $77.4 million for the same period in 2008.

11 Feb 2010

Quebec transplantation: 431 people receive 499 organs from 138 deceased donors

Owing to the generosity of Quebecers, 499 organs from 138 deceased donors in 2009 were transplanted into 431 recipients. Though there were 13 fewer donors than in 2008, Québec posted an average of more than 3.6 transplanted organs per deceased donor in 2009, placing the province among the leaders in Canada and even North America. "We're particularly proud of the sustained collaboration of professionals in hospitals in 2009," says Louis Beaulieu, chief executive officer of Québec-Transplant, the organization responsible for coordinating the organ donation process.

11 Feb 2010

DPC lauds passage of S.B. 316 dialysis care legislation

Dialysis Patient Citizens today praised the Senate Insurance and Labor Committee for unanimously passing legislation – S.B. 316 – which will increase patient access to life-saving dialysis care or transplant medications. Dialysis patients attending yesterday’s hearing encouraged lawmakers to support the bill which, if enacted, would greatly help approximately 2,000 Georgians suffering from kidney failure who are having difficulty accessing health insurance. Twenty-nine states across the country have enacted this popular legislation that is widely embraced by patients, family members and taxpayers.

11 Feb 2010

Allos Therapeutics' disease-specific registry for patients with PTCL enrolls first study participant

MedNet Solutions, a global life sciences technology solutions company specializing in clinical study management systems, is pleased to announce that Allos Therapeutics' new international disease-specific registry for patients with peripheral T-cell lymphoma (PTCL) has enrolled its first study participant.

11 Feb 2010

DMC recommends Gamida-Teva JV to continue enrollment in StemEx Phase III trial for leukemia and lymphoma

Elbit Imaging Ltd. announces that its associated company (approximately 28% holding on a fully diluted basis), Gamida Cell Ltd. ("Gamida Cell") through the Gamida-Teva Joint Venture (JV), announced today that the Data Monitoring Committee ("DMC") has independently reviewed preliminary data from the pivotal registration, Phase III clinical trial of StemEx (called ExCell) and has recommended that the JV continue to enroll patients in this study.

11 Feb 2010

LUHS nurses earn professional certifications

Several Loyola University Health System (LUHS) nurses have earned professional certifications in their clinical areas of expertise. This indicates that LUHS nurses meet strong professional development standards and competencies.

11 Feb 2010

CORD:USE Cord Blood Bank, Memorial Healthcare System announce partnership

CORD:USE Cord Blood Bank announced today that it is partnering with the Memorial Healthcare System, the fifth-largest public healthcare system in the nation, to collect umbilical cord blood that will be placed in a global registry for patients in need of a potentially life-saving transplant.

11 Feb 2010

Raptor Pharmaceutical to present DR Cysteamine trial data at Lysosomal Disease Network Symposium

Raptor Pharmaceutical Corp., today announced the presentation of cystinosis data at the Annual Lysosomal Disease Network WORLD Symposium 2010, being held February 10-12 in Miami, Florida. Biomarker data from a Phase IIb pilot study of Raptor's proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") will be the subject of a poster titled, "Correlation of Plasma Cysteamine and WBC Cystine Levels at Steady State in Patients Treated with Cysteamine Bitartrate." The results will also be published in an upcoming issue of the journal Molecular Genetics and Metabolism.

10 Feb 2010

Genzyme and Isis Pharmaceuticals: Phase 3 mipomersen study in heFH patients meets primary endpoint

Genzyme Corp. and Isis Pharmaceuticals Inc. today announced that the phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH) met its primary endpoint with a highly statistically significant 28 percent reduction in LDL-cholesterol after 26 weeks of treatment, compared with an increase of 5 percent for placebo.

10 Feb 2010

DMC recommends JV to continue enrolling patients in Phase III clinical trial of StemEx

The Gamida Cell-Teva Joint Venture (JV) announced today that the Data Monitoring Committee (DMC) has independently reviewed preliminary data from the pivotal registration, Phase III clinical trial of StemEx (called ExCell) and has recommended that the JV continue to enroll patients in this study.

10 Feb 2010

TBTC to receive more than $90 million to develop effective tuberculosis treatments

The Tuberculosis Trials Consortium (TBTC) strives to conduct research about the diagnosis, medical treatment, and prevention of tuberculosis (TB) infection and disease. The network is composed of a partnership of clinical investigators from the U.S. Centers for Disease Control and Prevention (CDC), public health departments from different countries, as well as medical and pharmaceutical institutions.

10 Feb 2010

Ligon Discovery, Lycera announce collaboration to identify drug candidates for immune disorders

Ligon Discovery announced today that it has entered into a collaboration agreement with Lycera Corporation to apply its Small Molecule Microarray (SMM) screening technology to identify first-in-class drug candidates for immune disorders. Ligon will apply its SMM technology to screen protein targets identified by Lycera as critical to the development of certain immune disorders. Financial terms were not disclosed.

10 Feb 2010

Innovative nerve graft transplant successful in treatment and prevention of posterior pressure ulcers

The Plastic Surgery Center today announced that an innovative nerve graft transplant performed by Dr. Andrew Elkwood has proven to be successful in treating and preventing posterior pressure ulcers – one of the leading causes of mortality among paraplegics. 49-year old Tory Cavalieri, who underwent the procedure last January, has regained sensation in his posterior and is free of acute pressure sores, which had left him bedridden for years.

9 Feb 2010

Kidney care advocates urge passage of key legislation for Georgia’s kidney patients

On Tuesday, February 9, kidney patients from across the state of Georgia will join Dialysis Patient Citizens (DPC) – a national, non-profit, patient-led organization representing approximately 1,300 members in Georgia and 22,000 members nationwide – in holding a briefing at the State Capitol, followed by a series of meetings with lawmakers and staff, urging the passage of key legislation this year that would help thousands of Georgia’s kidney failure patients who are struggling to access health insurance for the medical care they need.

6 Feb 2010

Valentine's Day designated as National Organ Donor Day, drive for registration

While many commemorate Valentine's Day with cards, candy and flowers, Pennsylvanians are encouraged to give the ultimate gift of love by signing up to become organ and tissue donors. With the support of the U.S. Department of Health and Human Services, Valentine's Day has been designated as National Organ Donor Day to raise awareness of the lives that can be touched -- potentially more than 50 at a time --through one person becoming an organ and tissue donor.

6 Feb 2010

News piece may highlight the importance of cord blood donation among Hispanic and Latino community

CORD:USE Cord Blood Bank and its program at South Miami Hospital are being featured on CNN en Espanol's show "Salud." This story on the importance of cord blood donation aired this week and can be seen Friday, February 5 at 9:30 a.m. EST and Sunday, February 7 at 9 a.m. EST and 3 p.m. EST on CNN en Espanol.

5 Feb 2010

Transplant News and Research

Genzyme announces 2-year data from eliglustat tartrate Phase 2 trial for Gaucher disease

NMDP Phase III filgrastim trial: Biologics to provide pharmacy management services

First FDA-approved umbilical cord blood stem cells infusion trial in children with cerebral palsy

PARI Pharma commences enrollment in L-CsA Phase 2b efficacy study

Alexion Pharmaceuticals announces financial results for quarter and year ended December 31, 2009

Quebec transplantation: 431 people receive 499 organs from 138 deceased donors

DPC lauds passage of S.B. 316 dialysis care legislation

Allos Therapeutics' disease-specific registry for patients with PTCL enrolls first study participant

DMC recommends Gamida-Teva JV to continue enrollment in StemEx Phase III trial for leukemia and lymphoma

LUHS nurses earn professional certifications

CORD:USE Cord Blood Bank, Memorial Healthcare System announce partnership

Raptor Pharmaceutical to present DR Cysteamine trial data at Lysosomal Disease Network Symposium

Genzyme and Isis Pharmaceuticals: Phase 3 mipomersen study in heFH patients meets primary endpoint

DMC recommends JV to continue enrolling patients in Phase III clinical trial of StemEx

TBTC to receive more than $90 million to develop effective tuberculosis treatments

Ligon Discovery, Lycera announce collaboration to identify drug candidates for immune disorders

Innovative nerve graft transplant successful in treatment and prevention of posterior pressure ulcers

Kidney care advocates urge passage of key legislation for Georgia’s kidney patients

Valentine's Day designated as National Organ Donor Day, drive for registration

News piece may highlight the importance of cord blood donation among Hispanic and Latino community

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News